Asana BioSciences acquires drug discovery platform from Endo
Asana BioSciences, an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International.
Asana is an R&D company specializing in the discovery and development of new chemical and biological entities, with a portfolio consisting of multiple oncology compounds and pain indications ready to enter clinical trials. Based in Bridgewater, N.J., Asana is led by Dr. Sandeep Gupta, CEO, who, until recently, was senior vice president of discovery and early development at Endo Pharmaceuticals.
Gupta said, “Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients. Our team consists of highly experienced scientists who have successfully executed several drug discovery and clinical development projects. I am very excited about this portfolio and am looking forward to initiating our first-in-man trials for our lead asset and moving other assets into clinical development.”